Apixaban for oral antithrombotic therapy: is a new era coming?
Abstract
Apixaban, a new oral inhibitor of activated factor Xa, may simplify antithrombotic therapy with fixed doses and no necessity for coagulation monitoring. Apixaban is non-inferior to conventional therapy (enxoaparin, followed by warfarin) with lower risk of major bleeding in the treatment of acute venous thromboembolism. Compared with placebo, extended treatment with apixaban may reduce the recurrence rate in patients with venous thromboembolism. Thromboprophylaxis therapy with apixaban in surgery (hip or knee replacement) and atrial fibrillation has been proved to be superior to warfarin or enxoaparin. Apixaban offers a convenient and more effective alternative choice in anticoagulant therapy.
Downloads
References
Agnelli G, Buller HR, Cohen A: Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013, 369: 799-808. 10.1056/NEJMoa1302507.
CrossRefPubMedGoogle Scholar
Agnelli G, Buller HR, Cohen A: Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013, 368: 699-708. 10.1056/NEJMoa1207541.
CrossRefPubMedGoogle Scholar
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P: Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010, 375: 807-15. 10.1016/S0140-6736(09)62125-5.
CrossRefPubMedGoogle Scholar
Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM: Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010, 363: 2487-98. 10.1056/NEJMoa1006885.
CrossRefPubMedGoogle Scholar
Granger CB, Alexander JH, McMurray JJ: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365: 981-92. 10.1056/NEJMoa1107039.
CrossRefPubMedGoogle Scholar
Goldhaber SZ, Leizorovicz A, Kakkar AK: Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011, 365: 2167-77. 10.1056/NEJMoa1110899.
CrossRefPubMedGoogle Scholar
Alexander JH, Lopes RD, James S: Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011, 365: 699-708. 10.1056/NEJMoa1105819.
CrossRefPubMedGoogle Scholar

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright
Copyright on any open access article in Molecular and Cellular Therapies published bythe Institute is retained by the author(s). Authors can grant any third party the right to use
the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified. Please contact the Office of Molecular and Cellular
Therapies for more information specifically regarding permissions if there are questions.